A DC vaccine (ICT-107) loaded with six synthetically processed GBM associated peptides (tumor stem cell antigen MAGE-1, her-2, AIM-2, Trp-2, gp100, and IL-13 Rα2) yielded improved progression-free survival and a trend toward improved survival in a randomized, double-blind, placebo-controlled phase II clinical trial for newly diagnosed GBM; however, the study did not meet the primary endpoint of improved overall survival (235). The gene discussed is AIM2; the disease is glioblastoma.